Strategikon Pharma, developer of a novel clinical trial planning, budgeting, outsourcing and vendor management tool, Clinical MaestroTM, has named Farah Ahmad as its new chief commercial officer, it was reported yesterday.
In this role, Farah will be responsible for strategy and implementation for market access and business development. Farah will report directly to founder and CEO, Anca Copaescu.
The company stated that Farah is a strategic and entrepreneurial business development leader with strong experience building successful sales teams, motivating top performers and driving growth in the clinical development segment. She joins Strategikon from Syneos Health, where she held the position of senior vice president, global business development leader for its Early Phase business unit.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study